<DOC>
	<DOCNO>NCT01307462</DOCNO>
	<brief_summary>This phase II trial study well give fluticasone propionate , azithromycin , montelukast sodium ( FAM ) together work treat patient bronchiolitis obliterans previously underwent stem cell transplant . FAM may effective treatment bronchiolitis obliterans</brief_summary>
	<brief_title>Targeted Therapy Bronchiolitis Obliterans Syndrome</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine combination treatment FAM administer post hematopoietic cell transplantation ( HCT ) recipients diagnosis new onset bronchiolitis obliterans syndrome ( BOS ) decrease rate treatment failure relative estimate historical rate 40 % use current therapy . SECONDARY OBJECTIVES : I . To confirm safety profile FAM . II . To describe effect standard pulmonary function test parameter : force expiratory flow 25 % -75 % forced vital capacity ( FVC ) ( FEF25-75 ) , residual volume ( RV ) , diffusion capacity carbon monoxide ( DLCO ) , forced expiratory volume 1 second ( FEV1 ) /FVC ratio FEV1/slow vital capacity ( SVC ) ratio FAM treatment . III . To determine change molecular marker inflammation fibrosis blood FAM treatment . IV . To assess impact FAM chronic graft-versus-host disease ( GVHD ) manifestation . V. To assess impact FAM functional status , health-related quality life ( HRQOL ) . VI . To describe change steroid dosing . OUTLINE : Patients receive fluticasone propionate inhale orally ( PO ) twice daily ( BID ) , azithromycin PO 3 day week , montelukast sodium PO daily ( QD ) . Treatment continue 6 month absence disease progression unacceptable toxicity . After completion study treatment , patient follow 6 month .</detailed_description>
	<mesh_term>Bronchiolitis</mesh_term>
	<mesh_term>Bronchiolitis Obliterans</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Diagnosis BOS HCT within 6 month study enrollment ; study , BOS define : Forced expiratory volume 1 second ( FEV1 ) &lt; 75 % predict normal FEV1 slow inspiratory vital capacity ratio ( FEV1/SVC FEV1/IVC ) = &lt; 0.7 , measure administration bronchodilator OR Pathologic diagnosis BOS demonstrate lung biopsy The baseline absolute FEV1 must &gt; = 10 % low pretransplant absolute FEV1 define pretransplant FEV1 minus baseline FEV1 , measure administration bronchodilator Participant ( parent/guardian ) ability understand willingness sign write consent document Recurrent progressive malignancy require anticancer treatment Known history allergy intolerance montelukast , zafirlukast , azithromycin , erythromycin , clarithromycin Pregnancy nursing ; female childbearing potential must negative serum urine pregnancy test &lt; 7 day study drug administration Transaminases &gt; 5 X upper limit normal ( ULN ) Total bilirubin &gt; 3 X ULN Chronic treatment inhale steroid &gt; 1 month past three month Treatment montelukast zafirlukast &gt; 1 month past three month Treatment prednisone &gt; 1.2 mg/kg/day ( equivalent steroid ) Treatment rifampin phenobarbital , aspirin dos &gt; 325 mg/day , ibuprofen dos &gt; 1200 mg/day Treatment Food Drug Administration ( FDA ) non approve study medication within past 4 week ; offlabel treatment FDAapproved medication allow Chronic oxygen therapy Evidence viral , bacterial fungal infection involve lung respond appropriate treatment Clinical asthma ( variable recur symptom airflow obstruction bronchial hyperresponsiveness ) Any condition , opinion enrol investigator , would interfere subject 's ability comply study requirement Uncontrolled substance abuse psychiatric disorder Inability perform pulmonary function test ( PFT ) reliably , determine enrol investigator PFT lab Life expectancy &lt; 6 month time enrollment judge enrol investigator Baseline postbronchodilator FEV1 &lt; 20 % predict normal albuterol</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>